Filtered By:
Specialty: Gastroenterology
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 4295 results found since Jan 2013.
Hepatic Manifestations of Nonhepatotropic Infectious Agents Including Severe Acute Respiratory Syndrome Coronavirus-2, Adenovirus, Herpes Simplex Virus, and Coxiella burnetii
Nonhepatotropic viruses such as adenovirus, herpes simplex virus, flaviviruses, filoviruses, and human herpes virus, and bacteria such as Coxiella burnetii, can cause liver injury mimicking acute hepatitis. Most of these organisms cause a self-limited infection. However, in immunocompromised patients, they can cause severe hepatitis or in some cases fulminant hepatic failure requiring an urgent liver transplant. Hepatic dysfunction is also commonly seen in patients with severe acute respiratory syndrome coronavirus-2 infection. Patients with preexisting liver diseases are likely at risk for severe coronavirus disease 2019 ...
Source: Gastroenterology Clinics of North America - April 23, 2021 Category: Gastroenterology Authors: Saeed Ali, Sameer Prakash, Arvind R. Murali Source Type: research
Type 2 Immunity and Age Modify Gene Expression of Coronavirus-induced Disease 2019 Receptors in Eosinophilic Gastrointestinal Disorders
Infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can lead to coronavirus-induced disease 2019 (COVID-19). The gastrointestinal (GI) tract is now an appreciated portal of infection. SARS-CoV-2 enters host cells via angiotensin-converting enzyme-2 (ACE2) and the serine protease TMPRSS2. Eosinophilic gastrointestinal disorders (EGIDs) are inflammatory conditions caused by chronic type 2 (T2) inflammation. the effects of the T2 atopic inflammatory milieu on SARS-COV-2 viral entry gene expression in the GI tract is poorly understood. We analyzed tissue ACE2 and TMPRSS2 gene expression in pediatric eos...
Source: Journal of Pediatric Gastroenterology and Nutrition - April 24, 2021 Category: Gastroenterology Tags: Short Communication: Gastroenterology: Eosinophilic GI Disorders Source Type: research
Coronavirus disease-2019 and the intestinal tract: An overview
World J Gastroenterol. 2021 Apr 7;27(13):1255-1266. doi: 10.3748/wjg.v27.i13.1255.ABSTRACTSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can progress to a severe respiratory and systemic disease named coronavirus disease-2019 (COVID-19). The most common symptoms are fever and respiratory discomfort. Nevertheless, gastrointestinal infections have been reported, with symptoms such as diarrhea, nausea, vomiting, abdominal pain, and lack of appetite. Importantly, SARS-CoV-2 can remain positive in fecal samples after nasopharyngeal clearance. After gastrointestinal SARS-CoV-2 infection and other viral ga...
Source: World Journal of Gastroenterology : WJG - April 9, 2021 Category: Gastroenterology Authors: Gabriela Gama Freire Alberca Rosa Liliana Solis-Castro Maria Edith Solis-Castro Ricardo Wesley Alberca Source Type: research
Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?
World J Gastroenterol. 2021 May 21;27(19):2270-2280. doi: 10.3748/wjg.v27.i19.2270.ABSTRACTCompelling evidence supports the crucial role of the receptor for advanced glycation end-products (RAGE) axis activation in many clinical entities. Since the beginning of the coronavirus disease 2019 pandemic, there is an increasing concern about the risk and handling of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in inflammatory gastrointestinal disorders, such as inflammatory bowel diseases (IBD). However, clinical data raised during pandemic suggests that IBD patients do not have an increased risk of con...
Source: World Journal of Gastroenterology : WJG - May 27, 2021 Category: Gastroenterology Authors: Armando Rojas Iv án Schneider Cristian Lindner Ileana Gonz àlez Miguel Angel Morales Source Type: research
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
Inflammatory bowel disease (IBD) patients with Crohn ’s disease and ulcerative colitis have been considered at increased risk of severe coronavirus disease 2019 (COVID-19) because they are often treated with immunosuppressive medications. Indeed, steroids and thiopurines in combination therapy with tumor necrosis factor (TNF) antagonists, but not TN F antagonist monotherapy, have been associated with a risk of severe COVID-19 in IBD patients.1,2 Expert consensus advocates that IBD patients should be vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Source: Gastroenterology - April 19, 2021 Category: Gastroenterology Authors: Serre-Yu Wong, Rebekah Dixon, Vicky Martinez Pazos, Sacha Gnjatic, Jean-Frederic Colombel, Ken Cadwell, ICARUS-IBD Working Group Tags: Brief Communication Source Type: research
